On June 23, 2021 Children’s Cancer Research Fund (CCRF) reported the support of OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS) and other deadly cancers in kids and adults (Press release, Children’s Cancer Research Fund, JUN 23, 2021, View Source [SID1234584299]). The investment, made possible by the Zach Sobiech Osteosarcoma Fund at CCRF, will help OS Therapies initiate a much-anticipated trial in Osteosarcoma: a deadly cancer of the bone that usually targets teenagers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Children’s Cancer Research Fund and Zach’s Fund are excited to join other non-profits, investors and OS Therapies to do something about this horrible disease," said Daniel Gumnit, CEO of CCRF. "OS Therapies is working to achieve the goals of CCRF, particularly to give every survivor of childhood cancer a long, healthy life after treatment."
Funding will support a national Phase IIb trial of 39 patients with Osteosarcoma that has returned (recurred) after initial treatment with failed chemotherapy and radiation. OST-HER2 (OST31-164 Listeria monocytogenes) stimulates the patient’s immune system to target the micro-metastasis seeking out soft tissue and oxygen so readily found in the lungs and brain.
"We are thrilled that CCRF would join us in this battle against Osteosarcoma. They are a leader in the research, advocacy and support of families and patients with childhood cancer," said Paul Romness, CEO of OS Therapies. "Fortunately, we have a technology that has shown great success in treating Osteosarcoma in dogs – now we need to see if it will work as well in our kids with OS."